RO7239361
CN001-016
Phase 3 small_molecule completed
Quick answer
RO7239361 for Duchenne Muscular Dystrophy is a Phase 3 program (small_molecule) at Hoffmann-La Roche with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Hoffmann-La Roche
- Indication
- Duchenne Muscular Dystrophy
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed